Search
Lenvatinib mesylate is used to treat hepatocellular carcinoma, non-small cell lung cancer, melanoma, breast cancer, lymphoma, ovarian cancer, etc.
Lenvatinib mesylate is a multi-target tyrosine kinase inhibitor with a novel binding mode that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2 and VEGF-3, in addition to inhibiting other proangiogenic and oncogenic signaling pathway-related tyrosine kinases involved in tumor proliferation.
| Items | Specifications | Results |
| Appearance | White powder | Conforms |
| Assay | ≥99.0% | 99.38% |
| Product parameters | |
| Cas number: | 857890-39-2 |
| Appearance: | White powder |
| Purity: | 99%min |
| Package details: | 1g/vial; 10g/PE bottle |
| Brand: | Fortunachem |

Used as antineoplastic agents.

Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!
Quick Links
Add:
E-mail:
English
Español
français
العربية